Adial Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Adial Pharmaceuticals

02/04/2024 22:01

* Adial Pharmaceuticals Inc  ADIL.OQ  reported a quarterly
adjusted loss of $1.35​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-2.75.  The mean expectation of
two analysts for the quarter was for a loss of 76 cents per
share. Wall Street expected results to range from -89 cents
to -63 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Adial Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.35​.
    * The company reported a quarterly loss of $1.92 million.
    * Adial Pharmaceuticals Inc shares had fallen by 7.5% this
quarter and lost 33.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 23.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Adial
Pharmaceuticals Inc is $17.00 
This summary was machine generated from LSEG data April 2 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.76          -1.35          Missed
 Sep. 30 2023      -1.13          -1.18          Missed
 Jun. 30 2023      -1.50          0.96           Beat
 Mar. 31 2023      -3.50          -2.75          Beat